At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
Under the direction of the Associate Director Marketing Hematology, this individual is responsible for the development and implementation of marketing campaigns and educational programs in the therapeutic area of multiple myeloma. Important is a high level of self-dependent and -responsible working. The incumbent actively drives the development of strategic brand plans and tactical implementation plans. Further the Brand Manager builds and maintains strong relationships with internal stakeholders, external vendors and opinion leaders in the market.
Responsibilities include, but are not limited to:
* Actively represents German team and - market requirements as member of the international / global Team / workstream (WWBT) in respective meetings, shapes product strategy to German market and shares best practices
* Develops marketing campaigns and ensures timely approval in accordance with regulatory requirements and in alignment with international / global strategy, branding etc.
* Ensures effective roll-out and implementation of marketing campaigns through briefing and training at cycle meetings
* Tracks campaign and tactical implementation as well as success; develops rapid counteractions if necessary
* Constantly seeks feedback and inspires sales team, being perceived as a highly passionate and persuasive brand champion
* Analyses and interprets market research data and incorporates findings into tactics and strategy in general and especially within strategic planning process
* Closely works together with market research in terms of competitive landscape-analysis,
-interpretation and respective intervention as well as in setting up new ideas for market evaluations
* Drives projects with KOLs resulting in data and publications that impact the national and international market
Skills/Knowledge Required:
* Natural science and/or Business Administration degree required
* Experience in Hemato-/Oncology, esp. Multiple Myeloma and/or Immunology preferred
* Professional experience in pharmaceutical industry as well as in marketing preferred
* Sales experience preferred
* Successful track record within pharmaceutical industry being an advantage
* Highly scientific working profile with the ability to simplify and interpret complex clinical data
* High level of creativity strongly associated to science
* Strong PC / Microsoft Office skills
* Ability to work with all levels of personnel and establish positive working relationships, especially with Sales- and Medical Team
* Strong analytical skills
* Strong presentation skills preferred
* Fluency in German and English, both oral and written
* Strong project management skills
* Highly positive attitude
* Good team player
* Strong identification with the company's values
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Summit, NJ
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.